Leonido Luznik, MD, Johns Hopkins University School of Medicine, Baltimore, MD, briefly discusses strategies being explored to prevent graft-versus-host disease (GvHD) in high-risk patients, commenting on the value of post-transplant cyclophosphamide (PTCy)-based approaches in this setting. Dr Luznik also discusses the possibility of combining PTCy with other agents, such as JAK inhibitors. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.